Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study

This publication has 27 references indexed in Scilit:

• Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
  The Lancet, 2020
• 2019-Novel Coronavirus (2019-nCoV): estimating the case fatality rate – a word of caution
  Swiss Medical Weekly, 2020
• Coronavirus infections and immune responses
  Journal of Medical Virology, 2020
• Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020
  Eurosurveillance, 2020
• Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
  Nature Communications, 2020
• The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib
  2019
• Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
  Annals of the Rheumatic Diseases, 2017
• JAKs and STATs in Immunity, Immunodeficiency, and Cancer
  New England Journal of Medicine, 2013
• Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
  Nature, 2003
• The American-European Consensus Conference On Ards. Definitions, Mechanisms, Relevant Outcomes, And Clinical Trial Coordination
  American Journal of Respiratory and Critical Care Medicine, 1994